Since crizotinib performed best drug selectivity for PCa in our screening (Fig. 5a), and AGR2 was the most significant DEP (Fig. 3a) between PCa- and BPH-derived primary cells, the significantly positive correlation (Spearman R = 0.58, p = 0.0027; Fig. 6a, b) between crizotinib and AGR2 was of considerable interest. The gene discussed is AGR2; the disease is benign prostatic hyperplasia.